This week, Alnylam Pharmaceuticals launched its latest attack in an intellectual property lawsuit filed against the Whitehead Institute for Biomedical Research, the University of Massachusetts, and the Massachusetts Institute of Technology, questioning UMass' claim to ownership of certain IP at the heart of the dispute (see related story, this issue).
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Browse our free articlesYou can still register for access to our free content.